Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 2/2024

14-07-2023 | Acute Myeloid Leukemia | Review Article

Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape

Authors: Eman T. Al-Antary, Avanti Gupte, Yaddanapudi Ravindranath

Published in: Indian Journal of Pediatrics | Issue 2/2024

Login to get access

Abstract

Acute myeloid leukemia (AML) accounts for 25% of all leukemia diagnosis and is characterized by distinct cytogenetic and molecular profile. Advances in the understanding of the causative driver mutations, risk-based therapy and better supportive care have led to an overall improvement in survival with frontline therapy. Despite these improvements, a significant number fail either because of primary refractory disease to the conventional 7+3 combination of anthracyclines and cytosine arabinoside (Cytarabine; Ara-C) or experience relapse post remission. Salvage therapy is complicated by the cardiotoxicity driven limitations on the reuse of anthracyclines and development of resistance to cytarabine. In this chapter authors will review the recent studies with targeted agents for refractory AML including targets for immunotherapeutic strategies.
Literature
1.
Stanchina M, Soong D, Zheng-Lin B, Watts JM, Taylor J. Advances in acute myeloid leukemia: Recently approved therapies and drugs in development. Cancers (Basel). 2020;12:3225.PubMedCrossRef
2.
3.
Zarnegar-Lumley S, Caldwell KJ, Rubnitz JE. Relapsed acute myeloid leukemia in children and adolescents: Current treatment options and future strategies. Leukemia. 2022;36:1951–60.PubMedCrossRef
4.
Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3–12.PubMedCrossRef
5.
Garg A, Ganguly S, Vishnubhatla S, Chopra A, Bakhshi S. Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study. Pediatr Blood Cancer. 2020;67:e28404.PubMedCrossRef
6.
7.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
8.
Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: A phase 1, dose-escalation study. Lancet Oncol. 2020;21:551–60.PubMedPubMedCentralCrossRef
9.
Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120:4621–34.PubMedPubMedCentralCrossRef
10.
McCall D, Roth M, Mahadeo KM, et al. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021;5:5215–9.PubMedPubMedCentralCrossRef
11.
Sharawat SK, Bakhshi R, Vishnubhatla S, Gupta R, Bakhshi S. FLT3-ITD mutation in relation to FLT3 expression in pediatric AML: A prospective study from India. Pediatr Hematol Oncol. 2014;31:131–7.PubMedCrossRef
12.
Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29:3293–300.PubMedPubMedCentralCrossRef
13.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.PubMedPubMedCentralCrossRef
14.
Zwaan CM, Söderhäll S, Brethon B, et al. A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. Br J Haematol. 2019;185:623–7.PubMedCrossRef
15.
Reinhardt D, Zwaan CM, Hoenekopp A, et al. Phase II study of midostaurin + chemotherapy in pediatric patients with untreated, newly diagnosed, FLT3-mutated acute myeloid leukemia (AML). Blood. 2019;134:3835.CrossRef
16.
Sharawat SK, Gupta R, Raina V, et al. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: Independent predictor of poor outcome in pediatric acute myeloid leukemia. Cytometry B Clin Cytom. 2013;84:390–7.PubMedCrossRef
17.
Tarlock K, Alonzo TA, Wang YC, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019;25:5038–48.PubMedPubMedCentralCrossRef
18.
Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660-73.e11.PubMedPubMedCentralCrossRef
19.
Brivio E, Baruchel A, Beishuizen A, et al. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. Eur J Cancer. 2022;164:1–17.PubMedCrossRef
20.
Shukla N, Wetmore C, O’Brien MM, et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia. Blood. 2016;128:2780.CrossRef
21.
Stein EM, Aldoss I, DiPersio JF, et al. Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: A phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101). Blood. 2021;138:699.CrossRef
22.
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8–13.PubMedCrossRef
23.
Newcombe AA, Gibson BES, Keeshan K. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Exp Hematol. 2018;63:1–11.PubMedCrossRef
24.
Krali O, Palle J, Bäcklin CL, et al. DNA methylation signatures predict cytogenetic subtype and outcome in pediatric acute myeloid leukemia (AML). Genes (Basel). 2021;12:895.PubMedCrossRef
25.
26.
DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98.PubMedCrossRef
27.
Sano H, Shimada A, Taki T, et al. RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: A study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;95:509–15.PubMedCrossRef
28.
Borthakur G, Popplewell L, Boyiadzis M, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122:1871–9.PubMedCrossRef
29.
Le Q, Hadland B, Smith JL, et al. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. J Clin Invest. 2022;132:e157101.PubMedPubMedCentralCrossRef
30.
Tang T, Le Q, Castro S, et al. Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate. Blood Adv. 2022;6:5933–7.PubMedPubMedCentralCrossRef
31.
Lamba JK, Chauhan L, Shin M, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: Report from randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2017;35:2674–82.PubMedPubMedCentralCrossRef
32.
Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response: Results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2016;34:747–55.PubMedPubMedCentralCrossRef
33.
Wang QS, Wang Y, Lv HY, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184–91.PubMedCrossRef
34.
Jin X, Zhang M, Sun R, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:88.PubMedPubMedCentralCrossRef
35.
Kim MY, Yu KR, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439–53.e19.PubMedPubMedCentralCrossRef
36.
37.
Lamble AJ, Eidenschink Brodersen L, Alonzo TA, et al. CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: A report from the Children’s Oncology Group. J Clin Oncol. 2022;40:252–61.PubMedCrossRef
38.
Johnson S, Burke S, Huang L, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399:436–49.PubMedCrossRef
39.
Barwe SP, Kisielewski A, Bonvini E, et al. Efficacy of flotetuzumab in combination with cytarabine in patient-derived xenograft models of pediatric acute myeloid leukemia. J Clin Med. 2022;11:1333.PubMedPubMedCentralCrossRef
40.
Angelova E, Audette C, Kovtun Y, et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019;104:749–55.PubMedPubMedCentralCrossRef
41.
Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628–37.PubMedCrossRef
42.
Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–85.PubMedPubMedCentralCrossRef
43.
Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99.PubMedPubMedCentralCrossRef
44.
Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37:946–53.PubMedPubMedCentralCrossRef
45.
Haddad F, Daver N. Targeting CD47/SIRPα in acute myeloid leukemia and myelodysplastic syndrome: Preclinical and clinical developments of magrolimab. J Immunother Precis Oncol. 2021;4:67–71.PubMedPubMedCentralCrossRef
46.
DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.PubMedPubMedCentralCrossRef
47.
Riether C, Schürch CM, Bührer ED, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214:359–80.PubMedPubMedCentralCrossRef
48.
Sauer T, Parikh K, Sharma S, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138:318–30.PubMedPubMedCentralCrossRef
49.
Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the Children’s Oncology Group. Blood. 2010;116:702–10.PubMedPubMedCentralCrossRef
50.
Augsberger C, Hänel G, Xu W, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021;138:2655–69.PubMedPubMedCentralCrossRef
51.
Rafiq S, Purdon TJ, Daniyan AF, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia. 2017;31:1788–97.PubMedCrossRef
52.
Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25:1064–72.PubMedPubMedCentralCrossRef
53.
Zhang H, Bu C, Peng Z, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: The multi-center efficacy and safety interim analysis. Leukemia. 2022;36:2596–604.PubMedCrossRef
54.
Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.PubMedCrossRef
55.
56.
57.
Berger KN, Pu JJ. PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene. Gene. 2018;638:20–5.PubMedCrossRef
58.
59.
Qian CS, Ma X, Wang J, et al. PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation. Bone Marrow Transplant. 2021;56:1003–5.PubMedCrossRef
60.
Broglie L, Gershan J, Burke MJ. Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. Int J Hematol Oncol. 2019;8:IJH10.
Metadata
Title
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
Authors
Eman T. Al-Antary
Avanti Gupte
Yaddanapudi Ravindranath
Publication date
14-07-2023
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 2/2024
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-023-04741-3

Other articles of this Issue 2/2024

Indian Journal of Pediatrics 2/2024 Go to the issue

Scientific Letter

Disseminated Tuberculosis in an Infant with IL-7 Receptor Deficiency

Picture of the Month

Cardiac Rhabdomyomas as a Cause of Neonatal Arrhythmias

Editorial Commentary

Pediatric Nausea Assessment Tool (PeNAT): Translation and Psychometric Evaluation in the Local Language is the Way Forward

Editorial Commentary

Navigating the Trachea: New Formula for Indian Children

Original Article

Characterization of the CYP21A2 Gene Mutations in Children with Classic Congenital Adrenal Hyperplasia

Editorial Commentary

Autoimmune Hemolytic Anemia, Inborn Errors of Immunity and Genetics: An Evolving Arena